Duitse aandelen Terug naar discussie overzicht

BAYER 2025

1. 4finance 15 mei 2025 09:02

   auteur info

   • 4finance

     Lid sinds: 24 jan 2014

     Laatste bezoek: 10 jul 2025

   • Aanbevelingen

     Ontvangen: 2933

     Gegeven: 2090

   •    Aantal posts: 9.420

   quote:

   Erny schreef op 14 mei 2025 14:03:

   Probleem is dat er nog tientallen jaren nieuwe claims binnen blijven stromen. En Europa kan nog volgen. Bewijs hoeft in de USA niet hard te zijn, emoties bij de jury wegen zwaarder. Gezien de hoogte van de reeds toegekende claims levert een eenvoudige rekensom op dat Bayer deze storm niet zal overleven. Bayer kan niet meer aan kapitaal komen, de assets zijn op een gegeven moment verkocht en een faillissement is daarna nog de enige uitkomst. Beleggers zijn dan alles kwijt en moeten dat moment voor zijn.
   

   Het ziet er inderdaad niet erg vrolijk uit bij BAYER met alle forse claims.
2. voda 16 mei 2025 06:26

   auteur info

   • voda

     Lid sinds: 02 dec 2005

     Laatste bezoek: 11 jul 2025

   • Aanbevelingen

     Ontvangen: 97314

     Gegeven: 23503

   •    Aantal posts: 391.517

   JPMorgan Cazenove geeft een houdadvies voor BAYER AG NA O.N.
   vrijdag 16 mei 2025 - 05:55u
   
   JPMorgan Cazenove geeft een koersdoel van € 25,00.
   
   www.guruwatch.nl/advies/179716/BAYER-...
3. LL 23 mei 2025 10:43

   auteur info

   • LL

     Lid sinds: 09 jan 2003

     Laatste bezoek: 11 jul 2025

   • Aanbevelingen

     Ontvangen: 4818

     Gegeven: 2726

   •    Aantal posts: 7.582

   Bayer: EU positive opinion for Eylea treatment
   09:46 23/05/2025
   
   (CercleFinance.com) - Bayer announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending an extension of the labeling for Eylea 8 mg.
   
   This extension allows treatment intervals to be extended up to 6 months for the treatment of two major retinal diseases, neovascular (wet) age-related macular degeneration (AMD) and diabetic macular edema (DME), following approval by the European Commission.
   
   The opinion of the Committee for Medicinal Products for Human Use (CHMP) is based on the results of the pivotal clinical trials PULSAR in neovascular (wet) age-related macular degeneration (AMD) and PHOTON in diabetic macular edema (DME).
   
   28% of patients with DME and 24% of patients with nAMD had a last treatment interval of 6 months after three years.
   
   The European Commission's decision is expected in the coming weeks.
   
   Following European Commission approval, extended treatment intervals of up to 6 months with Eylea can significantly reduce the frequency of injections and clinic visits for patients, Bayer said.
   
   Copyright (c) 2025 CercleFinance.com. All rights reserved.
4. LL 29 mei 2025 11:25

   auteur info

   • LL

     Lid sinds: 09 jan 2003

     Laatste bezoek: 11 jul 2025

   • Aanbevelingen

     Ontvangen: 4818

     Gegeven: 2726

   •    Aantal posts: 7.582

   Bayer's Monsanto loses appeal of $611M Roundup verdict in Missouri
   22:35 28/05/2025
   
   By Diana Novak Jones
   
   May 28 (Reuters) - A Missouri appellate court has upheld a $611 million verdict awarded to three people who sued Bayer alleging that its Roundup weedkiller caused their cancer, a ruling the company says it will further appeal.
   
   The decision from the Missouri Court of Appeals’ Western District on Tuesday rejected Bayer unit Monsanto’s argument that the lower court impermissibly allowed testimony at the 2023 trial about a ruling from the San Francisco-based 9th U.S. Circuit Court of Appeals in a separate case about the cancer risks of glyphosate, the pesticide in Roundup.
   
   Bayer is wrong in arguing that judicial opinions are categorically inadmissible at a jury trial, the court said. The court upheld the $611 million in compensatory and punitive damages awarded to Daniel Anderson, Jimmy Draeger and Valorie Gunther after their lawsuits were consolidated and tried before a jury.
   
   Bayer has faced thousands of lawsuits over whether Roundup causes cancer since it bought Monsanto for $63 billion in 2018. It agreed to settle much of that litigation for $10.9 billion in 2020, but failed to resolve future cases. About 67,000 remain, in both federal and state court.
   
   Though Bayer has prevailed in many of the Roundup trials, plaintiffs have won more than $4 billion of verdicts. Bayer has been pursuing appeals to reduce the verdict amounts while petitioning the U.S. Supreme Court to resolve a broader swath of the cases.
   
   One of Bayer's defenses in the litigation has been that the U.S. Environmental Protection Agency has determined that glyphosate doesn't pose a risk to human health.
   
   To counter that argument, the plaintiffs in Tuesday's case had told the jury that the 9th Circuit in 2022 found the EPA’s determination that glyphosate was not likely to cause cancer was not supported by the evidence and directed the agency to reexamine it.
   
   In a statement, a representative for Monsanto said the company will be seeking further review of the decision to allow the opinion to be presented to jurors.
   
   “In the majority of other cases which went to trial in Missouri, judges properly excluded inadmissible evidence, leading to positive outcomes for the Company,” the statement said.
   
   An attorney for the plaintiffs did not respond to requests for comment.
   
   The plaintiffs filed their lawsuits in 2022, claiming they each had been diagnosed with non-Hodgkin's lymphoma after years of using Roundup to control weeds.
   
   A Cole County, Missouri, jury found Monsanto liable for negligence, selling a defective product and failing to warn about Roundup's risks. They awarded $61.1 million of compensatory damages and $1.5 billion of punitive damages.
   
   In March 2024, the trial judge had let the $61.1 million component stand, but reduced punitive damages to nine times that amount, or $549.9 million. The U.S. Supreme Court has said that punitive damages should generally not be more than nine times compensatory damages.
   
   In Tuesday's decision, the appellate court also rejected another of the company's key arguments, that federal law blocks any state law claim that the company failed to warn consumers about the risks. The court agreed with another Missouri appellate district that found Monsanto had not shown an irreconcilable conflict between the federal and state laws.
   
   Thousands of other Roundup cases are pending in Missouri. Another trial over Roundup is underway in St. Louis. It is expected to last through mid-June.
   
   The case is Anderson v. Monsanto Co., Missouri Court of Appeals, Western District, No. WD87059.
   
   For Monsanto: Barbara Smith Tyson of Bryan Cave Leighton Paisner
   
   For the plaintiffs: Edward Robertson of Bartimus Frickleton Robertson Rader
   
   (Reporting by Diana Novak Jones in Chicago)
   
   Keywords: BAYER ROUNDUP/VERDICT
5. LL 2 juni 2025 10:46

   auteur info

   • LL

     Lid sinds: 09 jan 2003

     Laatste bezoek: 11 jul 2025

   • Aanbevelingen

     Ontvangen: 4818

     Gegeven: 2726

   •    Aantal posts: 7.582

   Bayer AG : Morgan Stanley raises target price to EUR 28 from EUR 26
6. LL 5 juni 2025 10:57

   auteur info

   • LL

     Lid sinds: 09 jan 2003

     Laatste bezoek: 11 jul 2025

   • Aanbevelingen

     Ontvangen: 4818

     Gegeven: 2726

   •    Aantal posts: 7.582

   BUZZ-GS ups Bayer to 'buy' citing pharma and litigation upsides, shares rise
   09:13 05/06/2025
   
   Shares in Bayer rise about 3.5% after Goldman Sachs upgraded the German chemicals group to "buy" from "neutral," citing positive newsflow on its Glyphosate litigation as well as positive risk/reward from its Phase 3 asundexian trials
   Should the Glyphosate litigation case be accepted for a review by the U.S. Supreme Court, there is potential towards largely removing the overhang, suggesting a 10-25% upside to the shares, GS says
   The legislative downside is relatively limited, it adds
   Goldman Sachs says Phase 3 data for oral Factor XIa (FXIa) inhibitor asundexian could be transformative, with 3 billion euros ($3.42 billion) peak sales at a 50% probability of success for OCEANIC-STROKE
   Out of 23 analysts covering Bayer, six rate it "buy"/ "strong buy;" 16 "hold;" and one "sell"
   Bayer shares top Germany's blue-chip <.GDAXI>
   ($1 = 0.8763 euros)
   
   (Reporting by Maria Rugamer)
   
   ((Maria.Rugamer@thomsonreuters.com))
7. LL 11 juni 2025 12:46

   auteur info

   • LL

     Lid sinds: 09 jan 2003

     Laatste bezoek: 11 jul 2025

   • Aanbevelingen

     Ontvangen: 4818

     Gegeven: 2726

   •    Aantal posts: 7.582

   Bayer : HSBC raises target price to EUR 32 from EUR 20
   Bayer : Kepler Cheuvreux raises to buy from hold
8. effegenoeg 11 juni 2025 12:58

   auteur info

   • effegenoeg

     Lid sinds: 30 jan 2013

     Laatste bezoek: 10 jul 2025

   • Aanbevelingen

     Ontvangen: 1712

     Gegeven: 224

   •    Aantal posts: 15.603

   quote:

   LL schreef op 11 juni 2025 12:46:

   Bayer : HSBC raises target price to EUR 32 from EUR 20
   Bayer : Kepler Cheuvreux raises to buy from hold
   

   Vraag me af wat de zienswijze is in de draaiende koopadviezen.
9. LL 11 juni 2025 13:13

   auteur info

   • LL

     Lid sinds: 09 jan 2003

     Laatste bezoek: 11 jul 2025

   • Aanbevelingen

     Ontvangen: 4818

     Gegeven: 2726

   •    Aantal posts: 7.582

   quote:

   effegenoeg schreef op 11 juni 2025 12:58:

   [...]
   
   Vraag me af wat de zienswijze is in de draaiende koopadviezen.
   

   Over de afgelopen periode is het fundament onder Bayer AG verbetert. Een aantal (aankomende) successen in de pipeline, verbeteringen in 2026 en een mogelijk uitspraak bij het hoger gerechtshof.
   
   Los van dit alles staat de koers er technisch gezien goed voor.
10. knakworst 12 juni 2025 14:59

    auteur info

    • knakworst

      Lid sinds: 19 jul 2024

      Laatste bezoek: 10 jul 2025

    • Aanbevelingen

      Ontvangen: 13

      Gegeven: 3

    •    Aantal posts: 29

    www.nieuweoogst.nl/nieuws/2025/06/12/...
    Uit het onderzoek onder leiding van Italiaanse wetenschappers blijkt dat ratten vaker kanker krijgen naarmate ze worden blootgesteld aan hogere doses glyfosaat en gewasbeschermingsmiddelen die daarvan worden gemaakt.
    
    Dweilen met de kraan open, wat mij betreft laat Bayer alle Monsanto entiteiten failliet gaan.
12. knakworst 12 juni 2025 15:01

    auteur info

    • knakworst

      Lid sinds: 19 jul 2024

      Laatste bezoek: 10 jul 2025

    • Aanbevelingen

      Ontvangen: 13

      Gegeven: 3

    •    Aantal posts: 29

    Conclusions
    
    Glyphosate and GBHs at exposure levels corresponding to the EU ADI and the EU NOAEL caused dose-related increases in incidence of multiple benign and malignant tumors in SD rats of both sexes. Early-life onset and mortality were observed for multiple tumors. These results provide robust evidence supporting IARC’s conclusion that there is“sufcient evidence of carcinogenicity [of glyphosate] in experimental animals”. Furthermore, our data are consistent with epidemiological evidence on the carcinogenicity of glyphosate and GBHs.
    
    cdn.nieuweoogst.nu/public/file/261522...
    
    Oftewel: Glyfosaat is kankerverwekkend voor ratten. Vrijwilligers die willen testen om te bepalen of dit ook voor mensen geldt?
13. LL 17 juni 2025 09:23

    auteur info

    • LL

      Lid sinds: 09 jan 2003

      Laatste bezoek: 11 jul 2025

    • Aanbevelingen

      Ontvangen: 4818

      Gegeven: 2726

    •    Aantal posts: 7.582

    Bayer AG Submits New Drug Application for Gadoquatrane to U.S. FDA, Seeks Approval for Low-Dose MRI Contrast Agent
    08:33 17/06/2025
    
    Bayer AG has announced the submission of their investigational contrast agent, gadoquatrane, to the U.S. Food and Drug Administration (FDA) for review. This New Drug Application seeks approval for gadoquatrane to be used in contrast-enhanced magnetic resonance imaging (MRI) of the central nervous system and other body regions in both adults and pediatric patients, including term neonates. The proposed dose represents a 60 percent reduction in gadolinium compared to existing macrocyclic GBCAs. If approved, gadoquatrane would become the lowest dose macrocyclic GBCA available in the U.S. The submission is supported by positive data from the Phase III QUANTI studies. Further regulatory applications are expected to be filed with health authorities worldwide in the coming months. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bayer AG published the original content used to generate this news brief on June 17, 2025, and is solely responsible for the information contained therein.
    
    (C) Copyright 2025 - Public Technologies (PUBT)
14. LL 27 juni 2025 19:30

    auteur info

    • LL

      Lid sinds: 09 jan 2003

      Laatste bezoek: 11 jul 2025

    • Aanbevelingen

      Ontvangen: 4818

      Gegeven: 2726

    •    Aantal posts: 7.582

    Bayer: EU approves treatment for AMD and DMO
    09:58 27/06/2025
    
    (CercleFinance.com) - The European Commission (EC) has approved Eylea 8mg with extended treatment intervals of up to 6 months for the treatment of two major retinal diseases, neovascular (wet) age-related macular degeneration (AMD) and visual impairment due to diabetic macular edema (DME).
    
    Eylea 8mg is the first and only vascular endothelial growth factor (VEGF) inhibitor treatment in the EU with treatment intervals of up to 6 months for patients with AMD and DME.
    
    The EC's decision is based on additional positive results from the open-label extension phase of the pivotal clinical trials PULSAR in AMD and PHOTON in DME.
    
    "Extending treatment intervals with Eylea 8 mg can significantly reduce the frequency of injections and clinic visits for patients without compromising efficacy," said Christine Roth, Executive Vice President, Global Product Strategy and Commercialization, and member of the Bayer Pharmaceuticals Leadership Team.
    
    "This translates into a reduced disease burden for patients and may improve treatment adherence."
    
    Eylea 8mg (aflibercept 8 mg) has been approved in more than 60 markets to date for the treatment of AMD and DMO.
    
    Copyright (c) 2025 CercleFinance.com. All rights reserved.
15. biobert 30 juni 2025 15:46

    auteur info

    • biobert

      Lid sinds: 19 jun 2000

      Laatste bezoek: 10 jul 2025

    • Aanbevelingen

      Ontvangen: 381

      Gegeven: 0

    •    Aantal posts: 1.232

    U.S. Supreme Court asks for views of Solicitor General in Durnell case
    
    Company expects decision on petition during beginning of the 2025-2026 Court session / Bayer continues its multipronged strategy to significantly contain the litigation by the end of 2026
    
    Leverkusen, June 30, 2025 – The U.S. Supreme Court today asked the Solicitor General to provide the Court with the views of the U.S. government in the Durnell case, following a petition for a writ of certiorari by Bayer’s indirect subsidiary Monsanto in April 2025.
    
    “We see this request as an encouraging step and look forward to hearing the views of the government on FIFRA’s federal preemption provision, which relies on language common to several federal laws that cover a number of industries,” said Bayer CEO Bill Anderson. “The security and affordability of the food supply depend on companies’ and farmers’ ability to rely on decisions made by responsible federal regulatory authorities. When courts permit companies to be punished under state law for following federal law, it makes companies like ours a prime target of the litigation industry and threatens farmers and innovations that patients and consumers need for their nutrition and health.”
    
    In its petition, the company argues that a split among federal circuit courts in the Roundup™ litigation warrants review and resolution by the country’s top court. The 3rd Circuit Court of Appeals unanimously held in the Schaffner case that the Federal Insecticide Fungicide and Rodenticide Act (FIRFA) expressly preempted the plaintiff’s state claims based on failure-to-warn theories. The 9th and 11th Circuits and Missouri’s intermediate appellate court in Durnell have reached different conclusions on the preemption question and the petition argues that both state and federal courts require guidance that only the U.S. Supreme Court can provide. Durnell is the first case for which Monsanto has sought Supreme Court review since the Schaffner decision created a split among the federal circuit courts.
    
    Once the Solicitor General provides its views, the Supreme Court will then make a decision on the company’s petition during the 2025-2026 Court session. If the Court accepts the case, a decision on the merits could still happen during the Court’s next session which ends in June 2026. A positive ruling on the central, cross-cutting issue in the Roundup™ litigation – whether federal law preempts claims based on state failure-to-warn theories – could help to largely contain this litigation.
    
    URL : www.bayer.com/media/en-us/us-supreme-...
    
    This is an automatically generated e-mail – please do not reply to it. If you have any queries please use our contact form.
    Unsubscribe // Privacy Statement
    
    To ensure proper mail delivery please add the following e-mail address to your contacts or the safe senders list: media-news@bayer.com
    
    © Bayer AG, Leverkusen, Germany
    
    © All rights reserved. The entire contents, including images, graphics, animations etc., of this e-mail and the server www.bayer.com are copyrighted.
    
    Board of Management: Bill Anderson, Chairman
    Wolfgang Nickl, Stefan Oelrich, Heike Prinz, Rodrigo Santos, Julio Triana
    Chairman of the Supervisory Board: Norbert Winkeljohann
    Registered office: Leverkusen | Local Court of Cologne, HRB 48248
16. voda 7 juli 2025 06:51

    auteur info

    • voda

      Lid sinds: 02 dec 2005

      Laatste bezoek: 11 jul 2025

    • Aanbevelingen

      Ontvangen: 97314

      Gegeven: 23503

    •    Aantal posts: 391.517

    Goldman Sachs herhaalt het koopadvies voor BAYER AG NA O.N.
    maandag 7 juli 2025 - 05:58u
    
    Het koersdoel wordt verhoogd van € 33,00 naar € 34,00. Het verwachte rendement is +31,00%.
    
    www.guruwatch.nl/advies/180753/BAYER-...
17. LL 8 juli 2025 17:40

    auteur info

    • LL

      Lid sinds: 09 jan 2003

      Laatste bezoek: 11 jul 2025

    • Aanbevelingen

      Ontvangen: 4818

      Gegeven: 2726

    •    Aantal posts: 7.582

    BRIEF-MHRA Approves Elinzanetant To Treat Moderate To Severe Vasomotor Symptoms Caused By Menopause
18. LL 10 juli 2025 15:51

    auteur info

    • LL

      Lid sinds: 09 jan 2003

      Laatste bezoek: 11 jul 2025

    • Aanbevelingen

      Ontvangen: 4818

      Gegeven: 2726

    •    Aantal posts: 7.582

    Bayer AG Seeks EU Approval for Low-Dose Gadoquatrane in MRI Scans, Aiming to Reduce Gadolinium Exposure
    08:32 10/07/2025
    
    Bayer AG has submitted a marketing authorization application to the European Medicines Agency (EMA) for its investigational contrast agent, gadoquatrane. This agent is designed for contrast-enhanced magnetic resonance imaging (MRI) to detect pathologies in all body regions, including the central nervous system, for both adults and pediatric patients, including neonates. The proposed gadoquatrane dose is 0.04 mmol of gadolinium per kilogram of body weight, representing a 60 percent reduction compared to standard macrocyclic gadolinium-based contrast agents. If approved, it would be the lowest dose macrocyclic GBCA available in the EU. This submission follows positive Phase III QUANTI study results and marks the first application for gadoquatrane's market authorization, with further regulatory applications planned globally. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bayer AG published the original content used to generate this news brief on July 10, 2025, and is solely responsible for the information contained therein.